{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    15,
    35,
    36,
    39,
    40,
    43
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Reference to Clinical Laboratory Tests Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from the Schedule of Activities table to Appendix 2 for details on laboratory tests."
      },
      {
        "id": "ref_2",
        "name": "Reference to Schedule of Activities",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9 to Section 2 for the timing of study procedures."
      },
      {
        "id": "ref_3",
        "name": "Reference to Laboratory Tests Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from Section 9 to Appendix 2 for a list of laboratory tests."
      },
      {
        "id": "ref_4",
        "name": "Reference to Blood Sampling Summary Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 5",
        "sectionTitle": "Blood Sampling Summary",
        "description": "Reference from Section 9 to Appendix 5 for a summary of invasive samples."
      },
      {
        "id": "ref_5",
        "name": "Reference to Post Glucagon Administration Procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2.3",
        "sectionTitle": "Post Glucagon Administration",
        "description": "Reference from Section 9.1 to Section 9.2.3 for details on plasma glucose level measurement."
      },
      {
        "id": "ref_6",
        "name": "Reference to Edinburgh Hypoglycemia Scale Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 7",
        "sectionTitle": "Edinburgh Hypoglycemia Scale",
        "description": "Reference from Section 9.1.3 to Appendix 7 for the Edinburgh Hypoglycemia Scale tool."
      },
      {
        "id": "ref_7",
        "name": "Reference to Schedule of Activities",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.1.3 to Section 2 for timing of hypoglycemia symptom assessment."
      },
      {
        "id": "ref_8",
        "name": "Reference to Clarke Hypoglycemia Awareness Survey Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 8",
        "sectionTitle": "Clarke Hypoglycemia Awareness Survey",
        "description": "Reference from Section 9.1.3 to Appendix 8 for the Clarke Hypoglycemia Awareness Survey tool."
      },
      {
        "id": "ref_9",
        "name": "Reference to Schedule of Activities",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.2.1 to Section 2 for timing of blood sample collection."
      },
      {
        "id": "ref_10",
        "name": "Reference to Treatment Details",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "Treatment",
        "description": "Reference from Section 9.2.2 to Section 7 for details on treatments."
      },
      {
        "id": "ref_11",
        "name": "Reference to Nasal and Non-nasal Score Questionnaire Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
        "description": "Reference from Section 9.2.2.1 to Appendix 6 for the Nasal and Non-nasal Score Questionnaire."
      },
      {
        "id": "ref_12",
        "name": "Reference to Nasal and Non-nasal Score Questionnaire Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
        "description": "Reference from Section 9.3.1.2 to Appendix 6 for the questionnaire."
      },
      {
        "id": "ref_13",
        "name": "Reference to Edinburgh Hypoglycemia Scale Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 7",
        "sectionTitle": "Edinburgh Hypoglycemia Scale",
        "description": "Reference from Section 9.3.1.2 to Appendix 7 for the scale."
      },
      {
        "id": "ref_14",
        "name": "Reference to Laboratory Tests Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from Section 9.5.1 to Appendix 2 for details on laboratory tests."
      },
      {
        "id": "ref_15",
        "name": "Reference to Schedule of Activities",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.5.1 to Section 2 for timing of laboratory tests."
      },
      {
        "id": "ref_16",
        "name": "Reference to Schedule of Activities",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.5.2 to Section 2 for timing of vital sign measurements."
      },
      {
        "id": "ref_17",
        "name": "Reference to Hepatic Monitoring Tests Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
        "description": "Reference from Section 9.5.5.2 to Appendix 4 for a list of liver tests."
      },
      {
        "id": "ref_18",
        "name": "Reference to Schedule of Activities",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.6 to Section 2 for timing of pharmacokinetic blood sample collection."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Confidentiality Statement",
        "pageNumber": 2
      },
      {
        "id": "annot_2",
        "text": "At Periods 1 and 2, samples should be collected from patients who have fasted at least 8 hours before any study procedures.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 16
      },
      {
        "id": "annot_3",
        "text": "If an SAE occurs after signing informed consent, but prior to receiving investigational product, AND is considered reasonably possibly related to a study procedure then it MUST be reported.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.3.1 Serious Adverse Events",
        "pageNumber": 40
      },
      {
        "id": "annot_4",
        "text": "Pregnancy (maternal or paternal exposure to investigational product) does not meet the definition of an AE. However, to fulfill regulatory requirements any pregnancy should be reported following the SAE process to collect data on the outcome for both mother and fetus.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.3.1 Serious Adverse Events",
        "pageNumber": 40
      },
      {
        "id": "annot_5",
        "text": "Only severe hypoglycemic episodes will be reported separately as AEs. If a hypoglycemic event meets the criteria of severe, it needs to be recorded as serious in the CRF (that is, recorded as an SAE).",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.5.5.1 Hypoglycemic Event Reporting",
        "pageNumber": 44
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "(a)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-12-05",
        "description": "Protocol I8R-JE-IGBJ, Amendment (a). The original protocol was electronically signed and approved on 2017-10-26.",
        "amendmentNumber": "Amendment (a)"
      }
    ],
    "summary": {
      "referenceCount": 18,
      "annotationCount": 5,
      "versionCount": 1
    }
  }
}